CiToxLAB increases capabilities in reprotoxicology and juvenile studies

Appoints Paul Barrow as director of scientific projects and client consulting

CiToxLAB, a French contract research organisation (CRO) involved in non-clinical research, has appointed Paul Barrow as director of scientific projects and client consulting.

Barrow has more than 30 years’ experience in preclinical safety testing, gained through working for the pharmaceutical industry and CROs in France, the UK and Italy.

Most recently Barrow was a director of toxicology at Ricerca Biosciences. In more than 10 years at Ricerca, he collaborated with more than 100 clients from the pharmaceutical, biotech, chemical and food industries to devise and execute non-clinical regulatory submission packages and to address pre- and post-marketing safety issues.

Barrow is a member of the Society of Toxicology, the Teratology Society, the European Teratology Society, Eurotox and is a European Registered Toxicologist.

You may also like

Research & Development

CiToxLAB expands inhalation test capabilities in North America and Europe

Opens rodent and non-rodent facility in Canada and will double rodent capacity in Hungary
Regulatory

CiToxLAB emerges from CIT and LAB Research merger

Will provide pre-clinical and specialist services from four facilities
Regulatory

CIT acquires assets of LAB Research Inc

This acquisition makes the new group one of the world’s top preclinical CROs
Research & Development

CIT to purchase LAB Research

Acquisition will take Canadian CRO out of receivership
Research & Development

Quotient Sciences and CPI to accelerate RNA drug development with joint venture

The JV will address the growing industry demand for agile solutions that bring new RNA therapeutics to patients with greater speed and confidence
Research & Development

Naobios, Nuvonis and the European Vaccine Initiative collaborate to manufacture influenza challenge agent

Working with the Inno4Vac consortium, Naobios will leverage Nuvonis’s Vero Cell Bank to support the development of a controlled human infection model based on the influenza virus A(H3N2)
Research & Development

Wegovy cuts risk of heart attack, stroke or death by 57% compared with tirzepatide

Study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to the semaglutide molecule and therefore cannot be extended to other GLP-1 or GIP/GLP-1-based treatments
Subscribe now